Antoinette R. Tan - Concepedia

Author

Antoinette R. Tan

Also Known As

A R Tan, A Tan, A. R. Tan, A. Tan, A.R. Tan, Ai-Leen Tan, Antoinette R Tan, Antoinette R. Tan, Antoinette Tan, Tan, Antoinette R.

231

Publications

9.6K

Citations

H-Index

Concepts

All Affiliations

Levine Cancer Institute Rutgers Cancer Institute Rutgers, The State University of New Jersey Dana-Farber Cancer Institute National Cancer Institute

About

Antoinette R. Tan is an author at Levine Cancer Institute specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	50	3.6K
2	Health Sciences	8	8	413
3	Cell Biology	6	6	206
4	Engineering	1	1	18
5	Biomolecular Engineering	1	1	18

Antoinette R. Tan

Publications

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study Sylvia Adams, P. Schmid, H. S. Rugo, Annals of Oncology	2018	756
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Sylvia Adams, Sherene Loi, Deborah Toppmeyer, Annals of Oncology	2018	608
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer Harold J. Burstein, Yan Sun, Luc Dirix, Journal of Clinical Oncology	2010	523
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma John C. Morris, Antoinette R. Tan, Thomas Olencki, PLoS ONE	2014	474
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im, The Lancet Oncology First-line TherapyBreast OncologyMedicinePharmacologyClinical Trials	2017	463
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer Shaveta Vinayak, Sara M. Tolaney, Lee S. Schwartzberg, JAMA Oncology	2019	413
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Hope S. Rugo, Jean‐Pierre Delord, Seock‐Ah Im, Clinical Cancer Research	2018	377
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane Linda T. Vahdat, Brian Pruitt, Carol J. Fabian, Journal of Clinical Oncology	2009	244
Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 Sherene Loi, Sylvia Adams, Peter Schmid, Annals of Oncology Breast OncologyCancer ImmunosurveillanceMedicineImmunologyTumor Immunity	2017	183

Page 1